HUP0200148A3 - Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention - Google Patents

Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention

Info

Publication number
HUP0200148A3
HUP0200148A3 HU0200148A HUP0200148A HUP0200148A3 HU P0200148 A3 HUP0200148 A3 HU P0200148A3 HU 0200148 A HU0200148 A HU 0200148A HU P0200148 A HUP0200148 A HU P0200148A HU P0200148 A3 HUP0200148 A3 HU P0200148A3
Authority
HU
Hungary
Prior art keywords
cinnamoyl
dimethoxy
prevention
reduction
events associated
Prior art date
Application number
HU0200148A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of HUP0200148A2 publication Critical patent/HUP0200148A2/hu
Publication of HUP0200148A3 publication Critical patent/HUP0200148A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HU0200148A 1999-02-03 2000-02-02 Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention HUP0200148A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11846399P 1999-02-03 1999-02-03

Publications (2)

Publication Number Publication Date
HUP0200148A2 HUP0200148A2 (hu) 2002-05-29
HUP0200148A3 true HUP0200148A3 (en) 2003-06-30

Family

ID=22378760

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200148A HUP0200148A3 (en) 1999-02-03 2000-02-02 Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention

Country Status (17)

Country Link
EP (1) EP1180027A4 (es)
JP (1) JP2002536326A (es)
KR (1) KR20010101933A (es)
CN (1) CN1338930A (es)
AR (1) AR022475A1 (es)
AU (1) AU2978500A (es)
BR (1) BR0007901A (es)
CA (1) CA2361578A1 (es)
CO (1) CO5160246A1 (es)
HU (1) HUP0200148A3 (es)
IL (1) IL144719A0 (es)
MX (1) MXPA01007833A (es)
NO (1) NO20013789L (es)
PL (1) PL349926A1 (es)
TR (1) TR200102262T2 (es)
WO (1) WO2000045810A1 (es)
ZA (1) ZA200106297B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097650B2 (en) * 2005-07-27 2012-01-17 The Trustees Of Columbia University In The City Of New York Method of treating a condition associated with phosphorylation of TASK-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617407B2 (ja) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤
WO1997009301A1 (fr) * 1995-09-07 1997-03-13 Kissei Pharmaceutical Co., Ltd. Derives de 2-acylaminobenzamide, preventif et remede contre des maladies causees par une surmultiplication des cellules vasculaires de l'intima
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention

Also Published As

Publication number Publication date
EP1180027A4 (en) 2004-11-17
AU2978500A (en) 2000-08-25
CO5160246A1 (es) 2002-05-30
PL349926A1 (en) 2002-10-21
NO20013789D0 (no) 2001-08-02
JP2002536326A (ja) 2002-10-29
WO2000045810A1 (en) 2000-08-10
AR022475A1 (es) 2002-09-04
MXPA01007833A (es) 2002-06-21
IL144719A0 (en) 2002-06-30
HUP0200148A2 (hu) 2002-05-29
ZA200106297B (en) 2002-07-31
KR20010101933A (ko) 2001-11-15
CN1338930A (zh) 2002-03-06
EP1180027A1 (en) 2002-02-20
NO20013789L (no) 2001-09-28
BR0007901A (pt) 2001-10-30
TR200102262T2 (tr) 2002-02-21
CA2361578A1 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
IL172695A0 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
IL145732A0 (en) α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
PL348349A1 (en) Antrhranilic acid amides and the use thereof as medicaments
HUP0200638A2 (en) Compounds derived from benzoic acid esters, composition containing said compounds and use thereof
HUP0102255A3 (en) Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
HU9500063D0 (en) Alfa-pyrimidinyl acrylic acid derivatives, the preparation thereof and their use as fungicide
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
PL353214A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
WO2000053182A3 (en) 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
HUP0200148A3 (en) Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention
GB9922710D0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
IT1271417B (it) Composti ad attivita' antiistaminica procedimento per la loro preperazione e composizioni farmaceutiche che li contengono.
HUP0201729A2 (en) Inhibitors of the integrin alpha v betha 6
HUP0200129A3 (en) Use of n-(3'4'-dimethoxycinnamoyl) anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention
PL355493A1 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use thereof as medicaments
EP1172359A4 (en) N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE, AND ITS USE AS AN INHIBITOR OF TNF PRODUCTION- $ g (a)
HK1045506A1 (en) Oxathiepino 6,5- i b /iÜdihydropyridines, and related compositions and methods
SI1235809T1 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use thereof as medicaments
IL129642A0 (en) Process for the preparation of optically active 1,4-benzodioxane-2- carboxylic acid and derivatives thereof
SI1214302T1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
EG23327A (en) Metraplant "iucd".
ZA200106261B (en) "The rostering of staff".
ZA997168B (en) "Shelving".
HUP0000679A3 (en) Use of 2,3,4,5-tetrahydro-1h-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders
ZA981918B (en) Use of 2,3,4,5-tetrahydro-1H-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders